Stephen Ansell
Enterprise Deputy Director and Senior Deputy Director, Midwest, Mayo Clinic Comprehensive Cancer Center · Mayo Clinic College of Medicine and Science
Credentials: · · · · · ·
History
PresentDivision of Hematology Department · Mayo Clinic College of Medicine and Science
- 1989–1991
Medical Oncology University of Pretoria
- 1986–1989
- 1982–1986
Research
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
New England Journal of Medicine · 2015 · First of 19 authors · 2,937 citations
Blood · 2022 · 1,363 citations
Journal of Clinical Oncology · 2012 · 1,166 citations
199 papers
188 papers
- DI
129 papers
124 papers
121 papers
- GN
118 papers
102 papers · 2 as a fellow
84 papers
Grants
- 1997–2025
Mayo Clinic Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $563.3K · Mayo Clinic Rochester
- 2002–2017
Lymphoma Specialized Program of Research Excellence (SPORE) in Human Cancer
National Cancer Institute · P50
Project lead · $3.9M · University of Iowa
- 2002–2013
Biologic Therapy for B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute · R01
Contact PI · $2M · Mayo Clinic Rochester
- 2007–2010
BLys Inhibition Using TACI-Fc in Patients with B-Bell Non-Hodgkins' Lymphoma
National Cancer Institute · R21
Contact PI · $562.4K · Mayo Clinic Rochester
Clinical trials
- 2023–2027
Principal investigator · Active not recruiting · Phase 2
Mayo Clinic
- 2018–2026
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
- 2017–2019
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Principal investigator · Terminated · Phase 2
Mayo Clinic
- 2005–2012
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)